Iovance Biotherapeutics, Inc. (IOVA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Iovance Biotherapeutics first quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Sarah Pellegrino, SVP, IR, and Corporate Communications. Please go ahead. Good afternoon, and thank you for joining the IOVANCE conference call and webcast to discuss our first quarter 2025 financial results, as well as recent corporate updates. Dr. Fred Vogt, our Interim Chief Executive Officer and President, We'll provide an introduction and focus on the U.S. commercial launch of Amtagvi, including revenue and revenue guidance. Dan Kirby, Chief Commercial Officer, will discuss the Amtagvi commercial launch. Dr. Igor Balinski, our Chief Operating Officer, will provide a manufacturing update. John Mark Bellaman, our CFO, will review our financial results, including revenue and revenue guidance, gross margin and cash burn guidance. and Dr. Frederick Pinkenstein, our Chief Medical Officer, will summarize key pipeline programs. Additional members of our leadership team, including Dr. Raj Puri, our Chief Regulatory Officer, Dr. Brian Gassman, our EVP of Medical Affairs, will be available for the Q&A session. Earlier this afternoon, we issued a press release that is available on our corporate website at iovance.com. Before we start, I would like to remind everyone that stateme...